Please login to the form below

Not currently logged in
Email:
Password:

EU approval for Gilenya

Novartis' oral multiple sclerosis drug Gilenya has been approved as the first treatment of its kind for use in the European Union

Novartis' oral multiple sclerosis (MS) drug Gilenya (fingolimod) has been approved as the first treatment of its kind for use in the European Union (EU).

The drug is approved for use in patients with highly active relapsing-remitting multiple sclerosis (RRMS) who have already undergone treatment with beta interferon, or have a rapidly evolving severe form of the condition.

The announcement follows the US Food and Drug Administration's (FDA) decision to approve Gilenya for use in the US after trials showed it reduced the frequency of relapse and reduced the risk of disease progression.

It has also been approved in other regions including Switzerland and Australia.

The EU approval was preceded by a positive opinion of Gilenya from the Committee for Medicinal Products for Human Use (CHMP), an expert committee of the European Medicines Agency (EMA).

Gilenya has fared better than other oral MS treatments, including Merck Serono's cladribine. Despite being approved in Russia under the trade name Movectro, it was recently denied US approval and was given a negative opinion by CHMP.

21st March 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

Women in science
The role of women in science and technology
Why the lack of female leaders in pharma and life sciences is a problem that still needs to be fixed...
Maria Dahl
China’s homecoming heroes fuel a biotech boom with rapid CAR-T advances
China secures a place at the forefront of innovative medicine...
Virtual Research Grants Submission and Approval Program
Impetus Digital summarizes how a client established an independent grant review committee and a virtual grant submission and approval program, without having to travel and meet in person....

Infographics